Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/59206
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFont, Rebeca-
dc.contributor.authorEspinàs Piñol, Josep Alfons-
dc.contributor.authorGil Gil, Miguel-
dc.contributor.authorBarnadas i Molins, Agustí-
dc.contributor.authorOjeda, B.-
dc.contributor.authorTusquets, Ignasi-
dc.contributor.authorSeguí, Miquel A.-
dc.contributor.authorMargelí Vila, Mireia-
dc.contributor.authorArcusa, Angels-
dc.contributor.authorPrat Marín, Andrés-
dc.contributor.authorGarcía, M.-
dc.contributor.authorBorràs Andrés, Josep Maria-
dc.date.accessioned2014-10-30T08:54:39Z-
dc.date.available2014-10-30T08:54:39Z-
dc.date.issued2012-09-06-
dc.identifier.issn0007-0920-
dc.identifier.urihttp://hdl.handle.net/2445/59206-
dc.description.abstractAIMS: To compare different methods in order to assess adherence and persistence with oral endocrine therapy in women diagnosed with breast cancer (BC) in Catalonia. MATERIALS AND METHODS: This study covered all women newly diagnosed with stage I, II or IIIa BC and positive hormone receptors at six hospitals in Catalonia (Spain) in 2004. Adherence was assessed on the basis of physician report and patient self-report using a telephone questionnaire. Persistence was measured by refill prescriptions. We used the Kappa index to compare adherence measures and logistic regression to evaluate adherence-related risk factors. RESULTS: The study covered a total of 692 women. Adherence ranged from 92% (self-report) to 94.7% (physician report), depending on the measure used; persistence was 74.7% at 5 years of follow-up. Low concordance between measures was observed (Kappa range: 0.018-0.267). Patients aged 50-74 years showed higher adherence than those aged <50 years. Adherence was also associated with: adjuvant chemotherapy and sequential hormonal therapy. CONCLUSIONS: Concordance between the different measures was remarkably low, indicating the need for further research. Adherence is an issue in the management of BC patients taking oral drugs, and should be assessed in clinical practice.eng
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherCancer Research UK-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1038/bjc.2012.389-
dc.relation.ispartofBritish Journal of Cancer, 2012, vol. 107, num. 8, p. 1249-1256-
dc.relation.urihttp://dx.doi.org/10.1038/bjc.2012.389-
dc.rightscc-by-nc-sa (c) Font,R. et al., 2012-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/es-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationCàncer de mamacat
dc.subject.classificationHormonoteràpiacat
dc.subject.classificationCatalunyacat
dc.subject.otherBreast cancereng
dc.subject.otherHormone therapyeng
dc.subject.otherCataloniaeng
dc.titlePrescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a restrospective cohort study in Catalonia, Spain.eng
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec626012-
dc.date.updated2014-10-30T08:54:39Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid22955858-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
626012.pdf312.1 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons